List of Resources on Transparency, Accountability and Participation of Covid-19 vaccines

Risks of acquiring vaccines

Title 

Abstract

Concerns about corruption in the distribution of the COVID-19 vaccine is one of the topics treated in this blog, as well as the actions that governments must do to ensure a safe and effective vaccine to those who need it. 

The podcast discusses some of the corruption risks associated with the delivery of vaccines and measures to ensure that the distribution of the Covid-19 vaccine is corruption-free so that it reaches those in most need of it. Also discusses key lessons from the COVID 19 response so far.

The article talks about the risks and concerns presented with the emerging vaccine for the COVID-19. Secretive bilateral deals and conflict of interests are topics treated in this document. 

Facing the distribution of the COVID-19 vaccine in a corrupt health environment is a challenge that countries are facing. To respond to this issue, the TI health initiative has been working with different agencies to minimize the corruption risks in the COVID-19 response. 

 

Vaccine roll out

Title 

Abstract

Diversion of vaccines and extortion are the most probable corruption situations associated with the distribution of the COVID-19 vaccine. This blog addresses this issue and explains with previous experiences of how this could happen. Finally, it also suggests some actions taken for the UNDP to coordinate actions to reduce the risks and effects of corruption.

In this blog, there are general recommendations to face corruption, build commissions for vaccines, public procurement, and protect vaccine distribution networks. 

With the current crisis, the EU and different countries are letting aside accountability and responsibility that pharmaceuticals must have in normal conditions. For instance, the EU Commission Strategy for COVID-19 Vaccines confirms that pharmaceuticals have successfully waived the responsibilities that usually are attributed to them if something goes wrong and now relies on purchasing countries.

 

Equitable access to vaccines 

Title

Abstract

The report contains recommendations to address the commitments needed to implement equitable allocation policies for the COVID-19 vaccine, a framework to assist policymakers in the domestic and global health communities, built on accepted foundational principles, and recognizing the distinctive characteristics of COVID-19

The analysis aims to support the identification of key issues and promote sharing of promising practices across the country while recognizing that the plans are initial drafts that will be refined by states and territories as they engage with the Centers for Disease Control and Prevention (CDC) and respond to new information and challenges that continue to emerge

The document addresses how countries are addressing equitable vaccine distribution and the massive vaccine to the population. A general overview reveals that only 30% of countries have developed processes to train a large number of vaccinators.

This document presents summary information on the next step in the field of vaccination: ensuring that the COVID-19 vaccines that are manufactured are distributed fairly and equitably. 

A new report from Médecins Sans Frontières (MSF) considers the effects of patents on access to pneumococcal conjugate vaccines (PCV) and human papillomavirus (HPV) vaccines – two important, yet expensive, new tools to protect people from preventable sickness and death.

This Human Rights Watch report examines key elements of a human rights-based approach to Covid-19 vaccines funding rooted in principles of transparency and accountability. It assesses how a variety of core rights—including but not limited to the rights to life, health, and an adequate standard of living—are being taken into account by governments.

The development of safe, efficacious vaccines to tackle the COVID-19 pandemic is an issue of global public concern. This  report by the Graduate Institute of Geneva and The Global Health Centre provides a clearer picture of who has invested how much, when, and where, is critical to understand better the distribution of risks and potential rewards, to shed light on how R&D investments may influence who gets access to the vaccines that result, and to inform future approaches to vaccine R&D.

Carlos Alberto Díaz